11.10.2016
Shop Apotheke Europe N.V. NL0012044747
DGAP-News: SHOP APOTHEKE EUROPE sets IPO price at EUR 28.00 per share
DGAP-News: Shop Apotheke Europe N.V. / Key word(s): IPO
SHOP APOTHEKE EUROPE sets IPO price at EUR 28.00 per share
11.10.2016 / 22:11
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA,
AUSTRALIA OR JAPAN.
SHOP APOTHEKE EUROPE sets IPO price at EUR 28.00 per share
- Gross primary proceeds of c. EUR 100 million
- Total placement volume including over-allotment of EUR 115 million
- IPO at final offer price several times subscribed
- Free-float at c.49% assuming full exercise of the greenshoe option
- Trading expected to start on 13 October 2016 in the Prime Standard of
the Frankfurt Stock Exchange
This press release also serves as the pricing statement pursuant to Section
5:18 paragraph 2 of the Dutch Financial Supervision Act (Wet op het
financieel toezicht) relating to the Offering and has been filed with the
Dutch Authority for the Financial Markets (Autoriteit Financiële Markten)
and is available on SHOP APOTHEKE EUROPE's website (http://shop-apotheke-
europe.com/en/investorrelations/boersengang/).
Venlo/Cologne, 11 October 2016. SHOP APOTHEKE EUROPE N.V. ("SHOP APOTHEKE
EUROPE" or the "Company"), one of the leading online pharmacies in
Continental Europe, in coordination with Berenberg and Citigroup as joint
global coordinators (the "Joint Global Coordinators") of the initial public
offering ("IPO" or "Offering"), has set the final offer price for SHOP
APOTHEKE EUROPE shares at EUR 28.00 per share.
Michael Köhler, CEO of SHOP APOTHEKE EUROPE, said: "We are delighted about
the strong demand. The team of SHOP APOTHEKE EUROPE is very excited about
taking the next steps in developing the company swiftly, which are unlocked
by the capital raise and the IPO. We are personally strongly committed to
enhance our leading market position in Continental Europe and aim for
creating long-term value for our shareholders, our customers and our
employees."
A total of 4,107,142 shares were placed with investors in the Offering,
thereof 3,571,428 newly issued ordinary bearer shares resulting from a
capital increase, corresponding to approximately EUR 100 million gross
proceeds for the Company. Further 535,714 ordinary bearer shares were
provided from the holdings of the current shareholders to cover over-
allotments.
At the final offer price the Initial Public Offering of SHOP APOTHEKE
EUROPE was several times subscribed. More than 99% of the shares have been
placed with institutional investors from Europe and the United States of
America and the remainder of the shares has been placed with retail
investors.
The total placement volume, including over-allotments, amounts to EUR 115
million.
Members of the managing board agreed to a 12-month lock-up. Additionally,
each of the other existing shareholders with a holding of more than 1% of
the share capital prior to the Offering as well as supervisory board
members with a shareholding in SHOP APOTHEKE EUROPE prior to the Offering
agreed to a 6-month lock-up.
As a result of the IPO and the related capital increase, the total share
capital of SHOP APOTHEKE EUROPE amounts to EUR 181,398 represented by
9,069,878 shares. The free float will amount to c.43% of the shares without
exercise of the greenshoe option and to c.49% if the greenshoe option is
exercised in full.
SHOP APOTHEKE EUROPE shares are expected to start trading on the Regulated
Market of the Frankfurt Stock Exchange (Prime Standard) under the ticker
symbol "SAE", the ISIN NL0012044747 and the German securities
identification number (WKN) A2AR94 on
13 October 2016.
Berenberg and Citigroup act as Joint Global Coordinators, and, together
with Commerzbank as Joint Bookrunners in connection with the IPO. Lilja &
Co. serves as independent advisor to the management and the owners of SHOP
APOTHEKE EUROPE. Parklane Capital acted as Financial Advisor to the
shareholders of SHOP APOTHEKE APOTHEKE.
About SHOP APOTHEKE EUROPE
SHOP APOTHEKE EUROPE is one of Continental Europe's leading online
pharmacies with a portfolio that focuses on OTC medication and pharmacy-
related BPC products. The Company operates online pharmacies in Germany,
Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany,
TÜV-certified shop-apotheke.com is the market leader in terms of traffic,
delivering a broad range of approximately 100,000 original products to
about 1.5 million active customers quickly and at a good price. In
addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent
pharmaceutical services.
SHOP APOTHEKE EUROPE generated over EUR 125 million in revenues in the
financial year 2015. Headquartered in Venlo (Netherlands), SHOP APOTHEKE
EUROPE also has an administration site for its sales and marketing units in
Cologne (Germany).
MEDIA CONTACTS
Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: [email protected]
Financial media:
Bettina Fries
Mobile: +49 172 297 62 43
Email: [email protected]
Disclaimer
This announcement does not, and shall not, in any circumstances constitute
a public offering, nor an offer to subscribe any securities in any
jurisdiction. The offering was made only on the basis of the securities
prospectus issued by the Company in connection with the offering. The
shares have already been sold.
This communication is not for publication or distribution, directly or
indirectly, in or into the United States, Canada, Australia or Japan. This
communication does not constitute or form part of an offer of securities
for sale or solicitation of an offer to purchase securities in the United
States, Canada, Australia, Japan or in any other jurisdiction in which such
offer may be restricted. The securities referred to in this communication
have not been, and will not be, registered under the US Securities Act of
1933, as amended (the "Securities Act"), and may not be offered or sold in
the United States, except on the basis of an applicable exemption from the
registration requirements or in a transaction not subject to the
registration requirements of the Securities Act. There will be no public
offering of securities in the United States.
In the United Kingdom, this communication is directed only at persons who:
(i) are qualified investors within the meaning of the Financial Services
and Markets Act 2000 (as amended) and any relevant implementing measures
and/or (ii) are outside the United Kingdom or (iii) have professional
experience in matters relating to investments and fall within the
definition of "investment professionals" contained in article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended) (the "Order") or are persons falling within article 49(2)(a)
to (d) (high net worth companies, unincorporated associations, etc.) of the
Order, or fall within another exemption to the Order (all such persons
referred to in (i) to (iii) above together being referred to as "Relevant
Persons"). Any person who is not a Relevant Person must not act or rely on
this communication or any of its contents. Any investment or investment
activity to which this communication relates is available only to Relevant
Persons and will be engaged in only with Relevant Persons.
This communication contains statements related to future business and
financial performance and future events or developments involving SHOP
APOTHEKE EUROPE that may constitute forward-looking statements.
These statements may be identified by words such as "expect", "intend",
"look forward to", "believe", "will" or other words of similar meaning.
Such statements are based on current expectations and certain assumptions
of SHOP APOTHEKE EUROPE's management, of which many are out of our control.
These are subjects to a number of risks and uncertainties. Should one or
more of this risks or uncertainties materialize, or should underlying
expectations not occur or assumptions prove incorrect, actual results,
performance or achievements of SHOP APOTHEKE EUROPE may (negatively or
positively) vary materially from those described explicitly or implicitly
in the relevant forward-looking statement. SHOP APOTHEKE EUROPE does not
intend or assume any obligation to update or revise these forward-looking
statements in light of developments which differ from those anticipated.
---------------------------------------------------------------------------
11.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Shop Apotheke Europe N.V.
Dirk Hartogweg 14
5928 LV Venlo
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747
WKN: A2AR94
Listed: Regulated Market in Frankfurt (Prime Standard)
Notierung vorgesehen / Intended to be listed: Frankfurt,
Prime Standard
End of News DGAP News Service
---------------------------------------------------------------------------
510893 11.10.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Shop Apotheke Europe N.V. ISIN: NL0012044747 können Sie bei EQS abrufen
E-Commerce , A2AR94 , RDC , XETR:RDC